Use Of Oral Itraconazole In Patients With Locally Limited Basocellular Carcinoma Of Skin.

• Status: Unknown status
• Trial end date: 2021-06-01
• Target enrollment: 0
• Participant gender: All

Summary

Patients with localized basocellular carcinoma of the skin, will receive oral Itraconazole, 200 mg twice daily, for 60 days, prior to curative intent surgery.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Hospital de Clinicas de Porto Alegre
• Treatments: Hydroxyitraconazole; Itraconazole

Criteria

Inclusion Criteria:

• Patients with diagnosis of Basocellular Carcinoma (BCC) of the Skin, histologically confirmed.

• At least one BCC lesion with 10 mm in the longest diameter

• Disease amenable to surgical intervention with curable intent.

• Signed Informed Consent

• PS ECOG 0 to 3

Exclusion Criteria:

• Chronic renal disease, with a glomerular filtration rate of less than 30 ml/min

• Acute or chronic liver disease, as measured by: total bilirubin > than 1.5 x ULN and AST and ALT > than 5 x ULN.

• Symptomatic cardiac insufficiency or an ejection fraction lower than 50% measured through echocardiography,

• Other active malignancies in the last year.

• Uncontrolled systemic hypertension,

• Any chronic infections such as tuberculosis, viral hepatitis and HIV.

• Pregnancy, suspected or confirmed.

• Known intolerance to the use of Itraconazole.